NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 82 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $368,000 | -41.4% | 575,000 | -5.7% | 0.15% | -46.3% |
| Q2 2022 | $628,000 | -57.7% | 610,000 | -22.8% | 0.28% | -38.6% |
| Q1 2022 | $1,485,000 | -70.6% | 790,000 | -24.6% | 0.46% | -57.0% |
| Q4 2021 | $5,048,000 | -33.3% | 1,047,300 | 0.0% | 1.07% | -24.3% |
| Q3 2021 | $7,572,000 | -29.0% | 1,047,300 | -9.4% | 1.41% | -20.2% |
| Q2 2021 | $10,672,000 | -29.2% | 1,156,200 | -5.6% | 1.77% | -20.0% |
| Q1 2021 | $15,080,000 | -22.9% | 1,225,000 | -11.6% | 2.22% | -13.2% |
| Q4 2020 | $19,547,000 | +17.5% | 1,386,300 | 0.0% | 2.55% | -21.5% |
| Q3 2020 | $16,636,000 | -28.4% | 1,386,300 | -1.0% | 3.25% | -30.7% |
| Q2 2020 | $23,240,000 | +45.9% | 1,400,000 | 0.0% | 4.69% | +11.2% |
| Q1 2020 | $15,932,000 | -6.4% | 1,400,000 | +1.4% | 4.22% | +26.4% |
| Q4 2019 | $17,018,000 | +500.1% | 1,381,300 | +38.8% | 3.34% | +225.4% |
| Q3 2019 | $2,836,000 | – | 995,000 | – | 1.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,291,133 | $1,166,187 | 1.01% |
| Privium Fund Management (UK) Ltd | 117,200 | $59,655 | 0.04% |
| Redmile Group, LLC | 1,850,566 | $941,938 | 0.04% |
| Baker Brothers Advisors | 3,821,740 | $1,945,266 | 0.01% |
| Kynam Capital Management, LP | 120,764 | $61,469 | 0.01% |
| Sio Capital Management, LLC | 38,312 | $19,501 | 0.01% |
| SIMON QUICK ADVISORS, LLC | 46,856 | $23,850 | 0.00% |
| Tri Locum Partners LP | 10,248 | $5,000 | 0.00% |
| Endurance Wealth Management, Inc. | 20,000 | $10 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 75,000 | $38,175 | 0.00% |